PT815218E - Oligonucleotido anti-sentido especificos para vegf humano - Google Patents

Oligonucleotido anti-sentido especificos para vegf humano

Info

Publication number: PT815218E
Authority: PT; Portugal
Prior art keywords: human vegf; sense specific; oligonucleotide anti; vegf; disclosed
Prior art date: 1995-03-02

Application number

PT96908608T

Other languages

English (en)

Inventor

Gregory S Robinson

Original Assignee

Hybridon Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-03-02

Filing date

1996-02-29

Publication date

2004-08-31

1995-03-02 Priority claimed from US08/398,945 external-priority patent/US5639872A/en

1996-02-29 Application filed by Hybridon Inc filed Critical Hybridon Inc

2004-08-31 Publication of PT815218E publication Critical patent/PT815218E/pt

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 3
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title abstract 3
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title abstract 3
230000000692 anti-sense effect Effects 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 2
206010029113 Neovascularisation Diseases 0.000 abstract 1
230000033115 angiogenesis Effects 0.000 abstract 1
230000000295 complement effect Effects 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C12N2310/3125—Methylphosphonates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/316—Phosphonothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Cardiology (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PT96908608T 1995-03-02 1996-02-29 Oligonucleotido anti-sentido especificos para vegf humano PT815218E (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/398,945 US5639872A (en)	1993-07-27	1995-03-02	Human VEGF-specific oligonucleotides
US08/569,926 US5641756A (en)	1993-07-27	1995-12-08	Modified VEGF oligonucleotides

Publications (1)

Publication Number	Publication Date
PT815218E true PT815218E (pt)	2004-08-31

Family

ID=27016436

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT96908608T PT815218E (pt)	1995-03-02	1996-02-29	Oligonucleotido anti-sentido especificos para vegf humano

Country Status (9)

Country	Link
US (1)	US5641756A (pt)
EP (2)	EP0815218B1 (pt)
JP (1)	JPH11501508A (pt)
AT (1)	ATE264912T1 (pt)
AU (1)	AU5179196A (pt)
DE (1)	DE69632250T2 (pt)
ES (1)	ES2216046T3 (pt)
PT (1)	PT815218E (pt)
WO (1)	WO1996027006A2 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0769552A4 (en) *	1994-06-27	1997-06-18	Toagosei Co Ltd	'ANTISENSE'NUCLEIC ACID COMPOSITION
MY134778A (en) *	1995-10-23	2007-12-31	Hyal Pharmaceutical Australia Ltd	Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization
AU721060B2 (en) *	1995-10-23	2000-06-22	Meditech Research Limited	Hyaluronic acid as DNA carrier for gene therapy and VEGF antisense DNA to treat abnormal retinal vascularization
CA2239991A1 (en) *	1995-12-08	1997-06-19	Hybridon, Inc.	Modified vegf antisense oligonucleotides
WO1997020925A1 (en) *	1995-12-08	1997-06-12	Hybridon, Inc.	Modified vegf antisense oligonucleotides for treatment of skin disorders
IL125756A (en)	1996-02-15	2003-05-29	Biosense Inc	Catheter for use in surgery
US6443974B1 (en) *	1996-07-28	2002-09-03	Biosense, Inc.	Electromagnetic cardiac biostimulation
US6291667B1 (en)	1997-01-31	2001-09-18	Parkash S. Gill	Method and composition for treatment of kaposi's sarcoma
US20020165174A1 (en) *	1997-01-31	2002-11-07	Gill Parkash S.	Methods and compositions for antisense VEGF oligonucleotides
WO1998039035A1 (en)	1997-03-07	1998-09-11	The Wistar Institute Of Anatomy & Biology	Method and compositions for healing tissue defects and inducing hypervascularity in mammalian tissue
EP0990042A1 (en) *	1997-06-10	2000-04-05	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Regulatory sequences involved in hypoxia regulated gene expression and uses thereof
JPH1142091A (ja) *	1997-07-25	1999-02-16	Toagosei Co Ltd	アンチセンス核酸化合物
US20030129750A1 (en) *	1998-02-05	2003-07-10	Yitzhack Schwartz	Homing of donor cells to a target zone in tissue using active therapeutics or substances
US20030113303A1 (en) *	1998-02-05	2003-06-19	Yitzhack Schwartz	Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances
DE69838526T2 (de)	1998-02-05	2008-07-03	Biosense Webster, Inc., Diamond Bar	Gerät zum Freisetzen eines Medikaments im Herzen
ES2389387T3 (es) *	1998-03-17	2012-10-25	Genentech, Inc.	Polipéptidos homólogos de VEGF y de BMP1
EP0978561A1 (en) *	1998-08-07	2000-02-09	Hoechst Marion Roussel Deutschland GmbH	Antisense oligonucleotides for the inhibition of VEGF expression
EP0979869A1 (en) *	1998-08-07	2000-02-16	Hoechst Marion Roussel Deutschland GmbH	Short oligonucleotides for the inhibition of VEGF expression
CN1307303C (zh) *	2000-01-19	2007-03-28	帕卡什·S·吉尔	针对反义vegf寡核苷酸的方法和组合物
EP1325121A2 (en) *	2000-10-13	2003-07-09	Institut de Cardiologie de Montreal	Antisense oligonucleotide directed toward mammalian vegf receptor genes and uses thereof
EP1414964B1 (en) *	2001-08-01	2010-03-24	University Of Bristol	Vegf isoform
WO2003018752A2 (en)	2001-08-23	2003-03-06	The Wistar Institute Of Anatomy And Biology	An organotypic intestinal culture and methods of use thereof
US20030096781A1 (en) *	2001-08-31	2003-05-22	University Of Southern California	IL-8 is an autocrine growth factor and a surrogate marker for Kaposi's sarcoma
US20050123925A1 (en)	2002-11-15	2005-06-09	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
FR2832154B1 (fr)	2001-11-09	2007-03-16	Centre Nat Rech Scient	Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
FR2836687A1 (fr) *	2002-03-04	2003-09-05	Gene Signal	Genes impliques dans la regulation de l'angiogenese, preparations pharmaceutiques les contenant et leurs applications
JP2006507841A (ja) *	2002-11-14	2006-03-09	ダーマコン，インコーポレイテッド	機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
WO2006006948A2 (en)	2002-11-14	2006-01-19	Dharmacon, Inc.	METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
NZ592039A (en)	2003-08-27	2013-03-28	Ophthotech Corp	Combination therapy for the treatment of ocular neovascular disorders
US20090155266A1 (en) *	2004-01-16	2009-06-18	Yale University	Methods and Compositions Relating to Vascular Endothelial Growth Factor and TH2 Mediated Inflammatory Diseases
EP1771474B1 (en) *	2004-07-20	2010-01-27	Genentech, Inc.	Inhibitors of angiopoietin-like 4 protein, combinations, and their use
US8604185B2 (en)	2004-07-20	2013-12-10	Genentech, Inc.	Inhibitors of angiopoietin-like 4 protein, combinations, and their use
FR2880631A1 (fr) *	2005-01-10	2006-07-14	Gene Signal	Genes impliques dans la regularisation de l'angiogenese, preparations pharmaceutiques les contenant et leurs applications
PT1877070E (pt) *	2005-05-05	2009-03-13	Antisense Pharma Gmbh	Utilização terapêutica de oligonucleótidos anti-sentido tgf-beta2
ES2354922B1 (es)	2009-09-02	2012-02-07	Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron	Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer.
JP2013539456A (ja)	2010-07-28	2013-10-24	アルコンリサーチ，リミテッド	ＶＥＧＦＡをターゲティングするｓｉＲＮＡ及びｉｎｖｉｖｏ治療のための方法
KR102948178B1 (ko)	2013-07-12	2026-04-10	아스텔라스 유에스 엘엘씨	안과적 질환을 치료하거나 예방하기 위한 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5731294A (en) *	1993-07-27	1998-03-24	Hybridon, Inc.	Inhibition of neovasularization using VEGF-specific oligonucleotides
US6410322B1 (en) *	1993-07-27	2002-06-25	Hybridon Inc	Antisense oligonucleotide inhibition of vascular endothelial growth factor expression

1995
- 1995-12-08 US US08/569,926 patent/US5641756A/en not_active Expired - Lifetime
1996
- 1996-02-29 AT AT96908608T patent/ATE264912T1/de not_active IP Right Cessation
- 1996-02-29 WO PCT/US1996/002840 patent/WO1996027006A2/en not_active Ceased
- 1996-02-29 PT PT96908608T patent/PT815218E/pt unknown
- 1996-02-29 DE DE69632250T patent/DE69632250T2/de not_active Expired - Lifetime
- 1996-02-29 JP JP8526431A patent/JPH11501508A/ja not_active Ceased
- 1996-02-29 EP EP96908608A patent/EP0815218B1/en not_active Expired - Lifetime
- 1996-02-29 EP EP04008228A patent/EP1443110A3/en not_active Withdrawn
- 1996-02-29 AU AU51791/96A patent/AU5179196A/en not_active Abandoned
- 1996-02-29 ES ES96908608T patent/ES2216046T3/es not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US5641756A (en)	1997-06-24
EP1443110A3 (en)	2005-01-12
ES2216046T3 (es)	2004-10-16
EP0815218A2 (en)	1998-01-07
DE69632250T2 (de)	2005-05-25
WO1996027006A2 (en)	1996-09-06
AU5179196A (en)	1996-09-18
JPH11501508A (ja)	1999-02-09
ATE264912T1 (de)	2004-05-15
WO1996027006A3 (en)	1996-10-17
EP0815218B1 (en)	2004-04-21
EP1443110A2 (en)	2004-08-04
DE69632250D1 (de)	2004-05-27

Publication	Publication Date	Title
ATE264912T1 (de)	2004-05-15	Antisense-oligonukleotide spezifisch für den menschlichen vegf
ATE234919T1 (de)	2003-04-15	Antisense nukleinsäuren zur vorbeugung und behandlung von beschwerden in welchen die exprimierung von c-erbb-2 eine rolle spielt
NL300406I1 (nl)	2009-11-02	Gesubstitueerde dihydrodibenzo (d,f)azepinen, werkwijze ter bereiding ervan, hun toepassing bij het behandelen van enkele verstoringen van het centraal zenuwsysteem, en farmaceutische samenstellingen die ze bevatten
MA26420A1 (fr)	2004-12-20	Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation.
MA26410A1 (fr)	2004-12-20	Formulations pharmaceutiques et procede pour leur production.
EP0925046A4 (en)	2000-02-23	TOPICAL PREPARATIONS AND METHODS FOR TREATING HEMORRHOIDS
DE69628864D1 (de)	2003-07-31	Invertierte chimäre und hybrid-oligonukleotide
DZ2523A1 (fr)	2003-02-01	Formulations pharmaceutiques contenant du voriconazole et procédé pour leur préparation.
ATE138384T1 (de)	1996-06-15	Olionukleotidalkylphosphonate und - phosphonothioate
NZ289028A (en)	1998-01-26	Use of antisense nucleic acids in the treatment of skin disease
GT199500007A (es)	1996-08-10	5 derivados sustituidos de acido micofenolico
IL112664A (en)	1999-06-20	4-amino derivatives of mycophenolic acid their preparation and pharmaceutical compositions containing them
DE69613348D1 (de)	2001-07-19	Hemmung der neovaskulasierung durch vegf-spezifische oligonukleotide
IL112667A (en)	2000-07-16	6-substituted derivatives of mycophenolic acid their preparation and pharmaceutical compositions containing them
FR2707882B1 (fr)	1997-08-01	Nouveaux kits thérapeutiques anti-médiateurs protéiques, procédé de préparation et compositions pharmaceutiques les renfermant.
DZ2414A1 (fr)	2003-01-04	2-amino-6-(2-substitué-4-phenoxy)substituté-pyridines procédé pour leur préparation et compositions pharmaceutiques les contenant.
EP1123414A4 (en)	2003-10-01	ANTISENSE MODULATION OF THE EXPRESSION OF INTEGRIN ALPHA 4
EP1430072A4 (en)	2005-02-16	ANTISENSE MODULATION OF THE EXPRESSION OF CHOLESTERYTERTERTRANSFERPROTEIN
AU1686997A (en)	1997-06-27	Modified vegf antisense oligonucleotides for treatment of skin disorders
ITRM960364A0 (it)	1996-05-28	Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
EP1250347A4 (en)	2004-03-17	ANTISENSE MODULATION OF THE AKT-3 EXPRESSION
HUP9900317A3 (en)	2001-10-29	Pharmaceutical composition useful for nucleic acid transfection, and use thereof
EP1165145A4 (en)	2003-03-05	ANTISENSE MODULATION OF THE MDMX EXPRESSION
TR199901385T2 (xx)	1999-11-22	Piperidin t�revleri.
IT9020072A0 (it)	1990-04-19	Cellule umane per l'elevata espressione di geni inseriti in dna ricombinanti episomiali,loro preparazione e loro impiego